Group 1 - The core point of the article is that Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical, has received approval from the National Medical Products Administration to conduct clinical trials for the drug Ketoprofen patch in China [1] - The drug is primarily intended for pain relief and anti-inflammatory treatment for conditions such as low back pain, osteoarthritis, shoulder periarthritis, tendonitis, and rheumatoid arthritis [1] - As of October 2025, the cumulative R&D investment for this drug by the group is approximately RMB 960,000 (unaudited) [1] Group 2 - According to IQVIA CHPA data, the sales revenue for Ketoprofen formulations in China is projected to be approximately RMB 91.16 million in 2024 [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical, has received approval from the National Medical Products Administration to conduct clinical trials for the ketoprofen patch in China, indicating a significant step in the development of this pain relief medication [1] Group 1: Clinical Trial Approval - The ketoprofen patch is intended for clinical trials in China, specifically for Phase III trials once conditions are met [1] - The drug is a chemical medication primarily aimed at treating pain and inflammation associated with various conditions, including lower back pain, osteoarthritis, and rheumatoid arthritis [1] Group 2: Research and Development Investment - As of October 2025, the cumulative R&D investment for the ketoprofen patch by the group is approximately RMB 960,000 (unaudited) [1] - The projected sales revenue for ketoprofen formulations in China for 2024 is estimated to be around RMB 91.16 million [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., has received approval from the National Medical Products Administration to conduct clinical trials for Ketorolac patches, indicating a significant step in the development of this pain relief medication [1] Group 1: Clinical Trial Approval - The approval allows for the initiation of Phase III clinical trials for the Ketorolac patches in China once conditions are met [1] - The drug is classified as a chemical medication and is intended for pain relief and anti-inflammatory treatment for various conditions [1] Group 2: Indications for Use - The Ketorolac patches are primarily aimed at treating pain and inflammation associated with conditions such as lower back pain, osteoarthritis, shoulder periarthritis, tendonitis, and muscle pain [1] - Additionally, the patches are indicated for local pain relief in rheumatoid arthritis [1]

Group 1 - The core point of the article is that Fosun Pharma's subsidiary Shanghai Fuhong Hanlin Biotech has received acceptance from the National Medical Products Administration for a drug registration application for a new indication of Sulfentanil injection, which is aimed at PD-L1 positive, resectable gastric cancer patients [1] - The application has been included in the priority review process by the regulatory authority [1] - Additionally, another subsidiary, Chaohui Pharmaceutical, has received approval from the National Medical Products Administration to conduct clinical trials for Ketorolac patch, which is intended for pain relief and anti-inflammatory purposes [1]

Core Viewpoint - Fosun Pharma (600196.SH) announced that its subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for the drug Ketorolac patch [1] Group 1 - The approval allows Chaohui Pharmaceutical to initiate Phase III clinical trials for the Ketorolac patch in China once conditions are met [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for the drug Ketorolac patch [1] Group 1 - The approval allows for the initiation of Phase III clinical trials for the Ketorolac patch in China once conditions are met [1]

Group 1: Company Strategy and Market Positioning - The company is focusing on three key areas for future strategic planning: expanding sales channels, increasing R&D efforts, and optimizing production processes to enhance operational efficiency and shareholder value [2] - The company aims to strengthen its presence in the outpatient market while enhancing brand influence, particularly for the "JiuYue" transdermal patch brand [3] - The company plans to launch several transdermal products, including Lidocaine Gel Patch and Indomethacin Gel Patch, expected to be approved in 2025, and Ketoprofen Patch and Flurbiprofen Patch in 2026 [4] Group 2: Product Development and Competition - The company believes that the market for external anti-inflammatory drugs is currently underserved, and the two products, Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch, will complement each other rather than compete [7] - The Loxoprofen Sodium Gel Patch has a high drug loading of 100mg per patch and is suitable for a wide range of conditions, while the Ketoprofen Gel Patch offers better drug permeability and efficacy for osteoarthritis [5] Group 3: Financial Projections and Market Risks - The company projects a revenue growth of 10-20% for the fiscal year 2025, with a similar expectation for net profit excluding non-recurring items [11][12] - The company acknowledges that its operational plans and product sales depend on various factors, including market conditions and industry policies, which introduce significant uncertainty [12] Group 4: Cost Management and Procurement Strategy - The company plans to reduce sales expenses by optimizing marketing strategies and expanding outpatient market reach [2] - The company maintains an integrated development strategy for raw materials and finished products, ensuring quality control and cost management through in-house production [10]